Effects of recombinant human growth hormone on basal metabolic rate in adults with pituitary deficiency.
The effect of recombinant human growth hormone (rhGH) on basal metabolic rate (BMR) was studied in a placebo-controlled, double-blind, crossover trial. Ten patients with a history of complete pituitary insufficiency were randomized for 26 weeks in each period. Three patients were excluded due to withdrawal, fever, and claustrophobia, respectively. All patients had received adrenal, thyroid, and gonadal substitution therapy for at least 1 year before the study. The dose of rhGH was 0.25 to 0.5 U/kg/wk, administered subcutaneously once a day in the evening. BMR was determined by indirect calorimetry in a computerized ventilated open-hood system. Body composition was examined using four different methods--computed tomography (CT), tritium dilution, 40K determinations, and total body nitrogen (TBN) measured with neutron activation. The body composition data have previously been reported. Fat-free mass (FFM) increased and body fat (BF) decreased during the first 6 weeks of rhGH treatment, but no further changes in body composition occurred between 6 and 26 weeks. Baseline BMRs in GH-deficient (GHD) patients were in the lower part of the reference range, but BMR and the ratio between BMR and FFM (BMR/FFM) were not significantly lower than in a carefully selected control group. BMR increased between 0 and 6 weeks (mean +/- SD: from 6.68 +/- 1.55 to 7.75 +/- 1.35 MJ/24 h, P < .001) and then remained unchanged between 6 and 26 weeks. The increase in BMR was closely related to the increase in FFM (r = .91, P < .01).(ABSTRACT TRUNCATED AT 250 WORDS)
Stenlöf
K
K
Department of Medicine, Diagnostic Radiology, Radiophysics, and Clinical Chemistry, Sahlgren's Hospital, University of Göteborg, Sweden.
Sjöström
L
L
Lönn
L
L
Bosaeus
I
I
Kvist
H
H
Tölli
J
J
Lindstedt
G
G
Bengtsson
B A
BA
D000328:Adult; D001481:Basal Metabolism / Q000187:drug effects*; D001823:Body Composition; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000494:pharmacology*; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D010446:Peptide Fragments / Q000378:metabolism; D010900:Pituitary Diseases / Q000378:metabolism* / Q000473:pathology; D011347:Procollagen / Q000378:metabolism; D011994:Recombinant Proteins; D012016:Reference Values; D013963:Thyroid Hormones / Q000378:metabolism
D010446:Peptide Fragments; D011347:Procollagen; D011994:Recombinant Proteins; D013963:Thyroid Hormones; C041876:procollagen Type III-N-terminal peptide; D013006:Growth Hormone